bimekizumab


( Last Updated : July 19, 2021)
Generic Name:
bimekizumab
Project Status:
Pending
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0698-000
Call for patient/clinician input closed:

Details


Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Anticipated Date: